The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma

European Journal of Haematology, 05/08/2012

Frontline use of bortezomib in a risk–adapted manner may avert early mortality and is better able to overcome adverse risks compared to its sequential use.

Print Article Summary Cat 2 CME Report